Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3.
Structure and ligand based pharmacophore modeling and docking studies carried out using diversified set of c-Jun N-terminal kinase-3 (JNK3) inhibitors are presented in this paper. Ligand based pharmacophore model (LBPM) was developed for 106 inhibitors of JNK3 using a training set of 21 compounds to reveal structural and chemical features necessary for these molecules to inhibit JNK3. Hypo1 consisted of two hydrogen bond acceptors (HBA), one hydrogen bond donor (HBD), and a hydrophobic (HY) feature with a correlation coefficient (r²) of 0.950. This pharmacophore model was validated using test set containing 85 inhibitors and had a good r² of 0.846. All the molecules were docked using Glide software and interestingly, all the docked conformations showed hydrogen bond interactions with important hinge region amino acids (Gln155 and Met149)and these interactions were compared with Hypo1 features. The results of ligand based pharmacophore model (LBPM)and docking studies are validated each other. The structure based pharmacophore model (SBPM) studies have identified additional features, two hydrogen bond donors and one hydrogen bond acceptor. The combination of these methodologies is useful in designing ideal pharmacophore which provides a powerful tool for the discovery of novel and selective JNK3 inhibitors.
Kumar
B V S Suneel
BV
bioCampus, GVK Biosciences Private Limited, S-1, Phase-1, TIE, Balanagar, Hyderabad 500037, India.
Kotla
Rohith
R
Buddiga
Revanth
R
Roy
Jyoti
J
Singh
Sardar Shamshair
SS
Gundla
Rambabu
R
Ravikumar
Muttineni
M
Sarma
Jagarlapudi A R P
JA
D020134:Catalytic Domain; D015195:Drug Design; D057927:Hydrophobic and Hydrophilic Interactions; D020128:Inhibitory Concentration 50; D008024:Ligands; D048057:Mitogen-Activated Protein Kinase 10 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D008958:Models, Molecular; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000378:metabolism; D021281:Quantitative Structure-Activity Relationship; D012984:Software
D008024:Ligands; D047428:Protein Kinase Inhibitors; D048057:Mitogen-Activated Protein Kinase 10
Neuron. 1995 Jan;14(1):67-78
7826642
EMBO J. 1996 Jun 3;15(11):2760-70
8654373
Expert Opin Investig Drugs. 2005 Nov;14(11):1373-83
16255677
Physiol Rev. 2001 Apr;81(2):807-69
11274345
J Med Chem. 2004 Mar 25;47(7):1739-49
15027865
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15184-9
14657393
J Med Chem. 2004 Mar 25;47(7):1750-9
15027866
J Chem Inf Model. 2006 Jul-Aug;46(4):1763-74
16859308
Chem Biol. 2003 Aug;10(8):705-12
12954329
J Neurosci. 2005 Jun 8;25(23):5533-43
15944381
Drug Discov Today. 2004 Nov 1;9(21):932-9
15501728
Bioorg Med Chem Lett. 2006 Nov 15;16(22):5917-25
16989998